Skip to main content
Patients at the support group, Matsanjeni clinic (Shiselweni region). In Eswatini, MSF is working to fight the dual epidemic of HIV and TB.
The treatment for DR forms of TB is long, sometimes over two years, and often has very difficult side-effects. MSF organizes support groups and provides counseling to patients to help them stick with their treatment.
International Activity Report 2018

Eswatini

A support group at Matsanjeni clinic, in Eswatini’s Shiselweni region, where MSF is working with the Ministry of Health to provide community-based care to people living with HIV and tuberculosis, April 2018.
© Fanny Hostettler/MSF
Ebola disease in DRC: find out how we're responding
Learn more
MSF in Eswatini in 2018 Despite a decrease in the number of new infections and deaths from HIV and tuberculosis (TB) in Eswatini (formerly Swaziland), controlling the spread remains a challenge.
Map showing location of MSF projects in 2018.
Map showing location of MSF projects in 2018.
© MSF

Almost one-third of adults in Eswatini are HIV positive,<a href="https://phia.icap.columbia.edu/wp-content/uploads/2017/11/Swaziland_new.v8.pdf">Swaziland HIV Incidence Survey 2 (SHIMS-2), 2016/2017; Mbabane, Eswatini</a> which also increases their vulnerability to TB and other infections. In this context, Médecins Sans Frontières continued to assist the Ministry of Health with prevention and care in Shiselweni region in 2018, while handing over some long-term activities to the ministry and partner organisations, such as our project in Manzini region, which began as an emergency intervention in 2010.  

Our emphasis in Eswatini is on community-based, patient-centred models of care and what is known as a ‘test and start’ strategy, which involves initiating antiretroviral (ARV) treatment at the time of diagnosis, irrespective of clinical criteria.  

We offer community-based testing for HIV and TB, oral HIV self-testing for hard-to-reach groups such as sex workers and men who have sex with men, and pre-exposure prophylaxis (PrEP) for people at increased risk of HIV infection. A total of 5,296 people accessed HIV self-testing and 468 were initiated on PrEP in 2018.   

Our teams provide specialised, integrated care for people living with HIV, including second- and third-line ARV therapy for those whose previous treatment has failed to work, and point-of-care screening and treatment for other diseases, such as cervical cancer, drug-resistant TB and cryptococcal meningitis, which commonly occur in people living with HIV.  

In 2018, 1,610 women were screened for cervical cancer, of whom 8 per cent tested positive. Of these, 67 per cent were treated. We provided prophylactic treatment for cryptococcal meningitis to 26 patients.